ArticleCancer science2021
Lack of GD3 synthase (St8sia1) attenuates malignant properties of gliomas in genetically engineered mouse model.
Article in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Sialylation in Thyroid Carcinoma: An Overview of Mechanisms, Markers, and Therapeutic Opportunities.Journal of Cancer · 2026Review
- Analyzing Molecular Complexes Containing Gangliosides via Co-Immunoprecipitation.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Ganglioside therapy in cancer molecular insights and therapeutic opportunities.Discover oncology · 2025Review
- The GD3 ganglioside promotes cell growth, plasticity and chemotherapy resistance of human glioblastoma cancer stem cells.Cancer cell international · 2025Article
- GD2 is a Crucial Ganglioside in the Signal Modulation and Application as a Target of Cancer Therapeutics.Cancer science · 2025Review
- Synergistic machine learning models utilizing ferroptosis-related genes for improved neuroblastoma outcome prediction.Translational pediatrics · 2024Article
- Crucial roles of exosomes secreted from ganglioside GD3/GD2-positive glioma cells in enhancement of the malignant phenotypes and signals of GD3/GD2-negative glioma cells.Nagoya journal of medical science · 2024Article
- Advances in Mass Spectrometry of Gangliosides Expressed in Brain Cancers.International journal of molecular sciences · 2024Review
- The good, the bad, and the unknown nature of decreased GD3 synthase expression.Frontiers in molecular neuroscience · 2024Article
- Article
- Review
- Possible regulation of ganglioside GD3 synthase gene expression with DNA methylation in human glioma cells.Glycoconjugate journal · 2023Article
- Recently developed glycosphingolipid probes and their dynamic behavior in cell plasma membranes as revealed by single-molecule imaging.Glycoconjugate journal · 2023Review
- The biological role and immunotherapy of gangliosides and GD3 synthase in cancers.Frontiers in cell and developmental biology · 2023Review
- Gangliosides in nervous system development, regeneration, and pathologies.Neural regeneration research · 2023Review
- Review
- Signaling domains of cancer-associated glycolipids.Glycoconjugate journal · 2022Review
- Role of GD3 Synthase ST8Sia I in Cancers.Cancers · 2022Review
- Editorial: Immunity in the development of anti-cancer drug resistance.Frontiers in pharmacology · 2022Article
- Lack of GD3 synthase (St8sia1) attenuates malignant properties of gliomas in genetically engineered mouse model.Cancer science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
High expression of gangliosides GD3 and GD2 is observed in human gliomas. The functions of GD3 and GD2 in malignant properties have been reported in glioma cells in vitro, but those functions have not yet been investigated in vivo. In this study, we showed that deficiency of GD3 synthase (GD3S, St8sia1) attenuated glioma progression and clinical and pathological features in a platelet-derived growth factor B-driven murine glioma model. Lack of GD3S resulted in the prolonged lifespan of glioma-bearing mice and low-grade pathology in generated gliomas. Correspondingly, they showed reduced phosphorylation levels of Akt, Erks, and Src family kinases in glioma tissues. A DNA microarray study revealed marked alteration in the expression of various genes, particularly in MMP family genes, in GD3S-deficient gliomas. Re-expression of GD3S restored expression of MMP9 in primary-cultured glioma cells. We also identified a transcription factor, Ap2α, expressed in parallel with GD3S expression, and showed that Ap2α was critical for the induction of MMP9 by transfection of its cDNA and luciferase reporter genes, and a ChIP assay. These findings suggest that GD3S enhances the progression of gliomas by enhancement of the Ap2α-MMP9 axis. This is the first report to describe the tumor-enhancing functions of GD3S in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.